Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

987955

registered interest
date	15/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Haemophilia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to commissioning criterion 6b of NHS England’s Criteria for the Prescribing of Enhanced Half-Life Blood Factors, published in September 2016; for what reason a maximum conversion ratio from Standard Half Life to EHL products was set; and whether a patient that achieved higher trough levels than before from a narrower conversion ratio would be switched back to their previous regimen.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	179162
answer	answer is ministerial correction date of answer 18/10/2018 answer text <p>The maximum conversion ratios were provided by clinical experts based on their experience of managing the clinical needs of most patients. Clinicians manage individual patients to achieve bleed control in line with the British Society of Haematology for trough levels, and bleed levels.</p><p> </p><p>The maximum conversion ratios apply only when switching from standard half-life (SHL) Factor IX (FIX) to and enhanced half-life (EHL) FIX. They do not apply when switching from an EHL FIX to an SHL FIX.</p><p> </p><p>Depending on individual patient need, it is possible that a patient could be switched to a previous or alternative regimen to achieve a target trough level greater than 1%.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/10/2018 16:11:50 answering member 4067 label Biography information for Steve Brine
tabling member	1533 label Biography information for Dame Diana Johnson

987956

registered interest
date	15/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Haemophilia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the paper entitled, The cost of severe haemophilia in Europe: the CHESS study published in the Orphanet journal of rare diseases in 2017, what assessment his Department has made of the reasons for (i) outcomes for patients and (ii) investment in treatments are lower in the UK than other EU5 countries; and what steps he is taking to improve treatment outcomes in the UK.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	179163
answer	answer is ministerial correction date of answer 18/10/2018 answer text <p>No such assessment has been made. The cost of blood factor products in the United Kingdom reflect successful commercial activities on price and clinical management such as universal access to prophylactic treatment regimens. These commercial activities enable the UK to achieve value for money when investing in providing access to treatment.</p><p> </p><p>The UK attracts many clinical studies in haemophilia, including those for new drugs or therapies which reduce the need for factor products altogether, based on its success in respect of managing haemophilia with prophylactic regimens.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/10/2018 16:14:32 answering member 4067 label Biography information for Steve Brine
tabling member	1533 label Biography information for Dame Diana Johnson

987957

registered interest
date	15/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Haemophilia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the World Federation of Haemophilia’s annual global survey, published in 2016, for what reason (a) Factor VIII and (b) Factor IX consumption per capita is lower in the UK than Ireland; and what assessment he has made of the adequacy of UK levels of factor (i) VIII and (ii) IX consumption to deliver appropriate outcomes for patients.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	179164
answer	answer is ministerial correction date of answer 18/10/2018 answer text <p>NHS England commissions treatments for haemophilia A and haemophilia B, and other bleeding disorders, according to the current British Society for Haematology clinical guidelines. Commissioned services report outcomes via a quality dashboard. Based on the data, NHS England considers that haemophilia population outcomes are adequate, and therefore has not undertaken an assessment of the adequacy of factor levels. This will continue to be monitored as new data becomes available.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/10/2018 16:08:22 answering member 4067 label Biography information for Steve Brine
tabling member	1533 label Biography information for Dame Diana Johnson

987959

registered interest
date	15/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Haemophilia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish the timescale for the completion of the tenders for (a) Factor VIII and (b) Factor IX blood products.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	179165
answer	answer is ministerial correction date of answer 18/10/2018 answer text <p>The current Commercial Medicines Unit (CMU) framework agreements that cover the stated products run from the following dates and have the following expiry dates and extension options:</p><p> </p><p>- NHS Framework Agreement for the Supply of Recombinant Factor VIII products for the treatment of bleeding disorders – commencement date 1 February 2018 / expiry date 31 January 2019 with options to extend up to a further 17 months. The CMU are working towards extending this framework agreement;</p><p>- NHS National Framework Agreement for the supply of Human Cell Line Recombinant Factor VIII products for the treatment of bleeding disorders – commencement date 1 July 2016 / expiry date 31 January 2019 with options to extend up to a further 17 months. The CMU are working towards extending this framework agreement;</p><p>- NHS National Framework Agreement for the supply of Recombinant Factor IX Blood Clotting Factors – commencement date 1 September 2016 / expiry date 28 February 2019 with options to extend up to a further 18 months. This framework is due to be re-tendered with the anticipated publication date of the OJEU Notice being early November 2018, tender timescales will be dependent on when this notice is issued; and</p><p>- NHS Framework Agreement for the supply of products for the treatment of bleeding disorders – commencement date 1 July 2018 / expiry date 30 June 2019 with options to extend up to a further 36 months.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/10/2018 16:15:12 answering member 4067 label Biography information for Steve Brine
tabling member	1533 label Biography information for Dame Diana Johnson

987960

registered interest
date	15/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Haemophilia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to commissioning criterion 6b of NHS England’s Criteria for the Prescribing of Enhanced Half-Life Blood Factors, published in September 2016, what assessment he has made of the appropriateness of maximum conversion ratios for children; and if he will direct NHS England to introduce a higher maximum conversion ratio for children as a result of their higher factor IX usage per kg of body weight.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	179166
answer	answer is ministerial correction date of answer 18/10/2018 answer text <p>NHS England’s criteria for the Prescribing of Enhanced Half-Life Blood Factors were produced by clinical experts. The conversion ratio is applied in the situation of switching a patient from a standard half-life Factor IX (FIX) to an enhanced half-life FIX. As higher doses of FIX may be just as likely in paediatric patients, regardless of whether the FIX is a standard or enhanced half-life product, the conversion ratios accommodate higher doses (on a unit per kilo gram bodyweight basis) if these are clinically indicated for the patient, irrespective of age. On this basis, NHS England does not have any current plans to amend the conversion ratios.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/10/2018 16:10:59 answering member 4067 label Biography information for Steve Brine
tabling member	1533 label Biography information for Dame Diana Johnson